89.32 +0.63 (0.71%)
Pre-Market: 9:21AM EST
|Bid||88.66 x 1000|
|Ask||89.38 x 1800|
|Day's Range||87.90 - 89.36|
|52 Week Range||77.50 - 125.86|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||18.52|
|Earnings Date||Jan 25, 2019|
|Forward Dividend & Yield||4.28 (4.91%)|
|1y Target Est||97.18|
J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.
A high degree of financial leverage means high interest payments, which affect the company's bottom line. So, investors try to avoid stocks that bear large debt loads
# AbbVie Inc ### NYSE:ABBV View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABBV totaled $1.80 billion. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.
Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
World Economic Forum gathers in Davos, Switzerland, government shutdown continues and earnings week two, here's what you need to know next week.
When most people think of marijuana stocks, the last thing they think of is dividends. The legal marijuana industry is still very young, and new companies in growing industries need money to expand. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges.
The founder and president of Delphi Management likes U.S. Bancorp, AbbVie, Disney, Lockheed Martin, Hercules Capital, and, for the faint of heart, U.S. Treasury paper.
AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, Imbruvica, failed to show statistically significant improvement in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients, compared with the combination of placebo and two chemotherapy agents. The American Cancer society estimates that pancreatic cancer accounts for about 3 percent of all cancers in the United States and about 7 percent of all cancer deaths, and expects that 56,770 people will be diagnosed with pancreatic cancer in 2019.
AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, ibrutinib, ...
-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents -- The study did ...
AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
# AbbVie Inc ### NYSE:ABBV View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $8.00 billion over the last one-month into ETFs that hold ABBV are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Dividend investing is back in fashion as wild price swings in the stock market and prolonged uncertainties weigh on investor sentiment. Retail companies enjoyed a strong holiday season but online sales continue to eat into brick-and-mortar shops’ margins. Brazil came third as the nation’s stock market soared to all-time highs on positive momentum. Biotechnology shares marked a major reversal on mergers and encouraging trial data. Small caps closed the list as some investors are adding them back to their portfolios. Check out our previous Trends edition at Trending: Brazil Welcomes New President in Hope of Economic Resurgence.
Healthcare stocks cover a wide range of equities. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category. However, these companies all benefit from the same trends. The share of healthcare in the overall U.S. economy continues to grow. The Centers for Medicare and Medicaid Services (CMS) estimates that healthcare encompasses about 17.9% of the U.S. economy. Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount. * 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. With more of the baby boom generation on Medicare, a larger percentage of the population benefits from a healthcare subsidy. This gives a noticeable boost to healthcare stocks. Here are three that could help you benefit from this trend. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE:ABBV). Abbott Laboratories (NYSE:ABT) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Today it trades at about 30% below its 52-week high. However, ABBV stock also looks well-positioned to make a comeback. The Humira-driven swoon in ABBV has taken the forward P/E ratio to around 9.8. This comes in well below the average P/E of 18.2 over the last five years. Moreover, Evaluate Pharma ranks AbbVie's drug pipeline as second-best in the industry for value creation. Also, the company has time to transition to its next high-revenue drug. It will hold a patent on Humira in the U.S. until at least 2022. Analysts also do not seem worried as they predict profit growth of almost 10% per year through at least 2021. Furthermore, Wall Street considers AbbVie a dividend aristocrat due to its previous ties to Abbott. As a result, the company faces tremendous pressure to increase its dividend annually. AbbVie increased its payout from $3.59 per share to $4.28 per share this year. Hence, despite a generous yield of almost 4.9%, investors can probably expect annual increases in future years. Also, I see this massive dividend increase as a vote of confidence in itself. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories. ### Teladoc Health (TDOC) Source: MayApps207 via WikiMedia Buying Teladoc Health (NYSE:TDOC) amounts to buying into the future of healthcare. Without a doubt, the 17.9% of the economy that healthcare now consumes weighs heavily on family budgets. Teladoc allows patients to see a licensed doctor at any time via a PC or mobile device, reducing the need to take time off from work. It also saves money as visits can run as low as $40. Telehealth has only begun to realize its potential. Analysts estimate telehealth can handle about one-third of the 1.25 billion office visits that take place each year in the U.S. With Teladoc handling an estimated two million visits in 2018, the company still covers less than 1% of its potential market. Teladoc also shows that it can acquire the right partners to improve its quality and reach more patients. It widened its competitive moat by investing in diagnostic capabilities with a takeover of Best Doctors. It also partnered with CVS Health (NYSE:CVS) to provide care to its customers. Additionally, it boosted its offshore footprint by buying Advance Medical. Advance Medical was the leading telehealth provider outside the U.S. before TDOC purchased the company. Investors should note that TDOC remains expensive. Its price in the $55 per share range places it at around 9.3 times sales. Still, it has fallen almost 40% from its October high. Also, revenue grew by 78% in 2018. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021. * 10 Growth Stocks With the Future Written All Over Them Teladoc remains one of the more speculative healthcare stocks. However, with a $3.8 billion market cap, and a majority market share in a business that has reached less than one percent of its full potential, Teladoc could become one of the best stocks in healthcare. ### Dentsply Sirona (XRAY) Source: Shutterstock An aging population creates an increasing need for dental care and the equipment provided by Dentsply Sirona (NASDAQ:XRAY). As the ticker implies, Dentsply manufactures dental imaging equipment as well as consumable supplies and specialty dental products. Medicare rarely covers dental needs. However, many consumers place a high value on having a beautiful smile and the ability to chew food. Hence, most customers will spend money on services requiring XRAY's supplies and equipment. This also holds true outside of the U.S. Dentsply Sirona conducts business in over 120 countries. These other countries account for about 65% of the company's revenue. XRAY stock rose steadily between 2009 and 2018. However, in 2018, the stock lost almost half of its value. By late October, it traded as low as $33.93 per share, a level first seen in 2011. The stock sold off for most of the year on lower-than-expected sales. An impairment charge on goodwill and intangible assets in the second quarter hurt earnings. The stock fell by nearly 20% on August 7 following this announcement. However, management responded with a restructuring plan. While that breeds uncertainty, the forecasts indicate an opportunity for buyers. The forward P/E ratio stands at around 18, well below the five-year average of 28.1. Furthermore, analysts predict 11.2% consensus profit growth this year. They also foresee double-digit profit increases through at least 2021. XRAY faced a great deal of pain in 2018. Still, the need for dental supplies and equipment will only rise in the coming years. For this reason, the lower multiple and the predicted profit growth should bring about a recovery in Dentsply Sirona. As of this writing, Will Healy is long TDOC stock. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Healthcare Stocks That Will Keep Your Portfolio Healthy appeared first on InvestorPlace.